Stocks and Investing Stocks and Investing
Tue, January 30, 2018
Mon, January 29, 2018
Fri, January 26, 2018

Andrew Fein Maintained (BIIB) at Strong Buy with Increased Target to $363 on, Jan 26th, 2018


Published on 2024-10-26 02:16:34 - WOPRAI, Andrew Fein
  Print publication without navigation


Andrew Fein of HC Wainwright & Co., Maintained "Biogen Inc." (BIIB) at Strong Buy with Increased Target from $340 to $363 on, Jan 26th, 2018.

Andrew has made no other calls on BIIB in the last 4 months.



There are 11 other peers that have a rating on BIIB. Out of the 11 peers that are also analyzing BIIB, 3 agree with Andrew's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Sumant Kulkarni of "Canaccord Genuity" Maintained at Hold with Increased Target to $350 on, Wednesday, January 24th, 2018
  • Carter Gould of "UBS" Maintained at Hold with Increased Target to $318 on, Wednesday, October 25th, 2017
  • Robyn Karnauskas of "Citigroup" Downgraded from Strong Buy to Hold on, Monday, October 23rd, 2017


These are the ratings of the 8 analyists that currently disagree with Andrew


  • Ian Somaiya of "BMO Capital" Maintained at Buy with Increased Target to $386 on, Monday, November 6th, 2017
  • Jeffrey Silber of "BMO Capital" Upgraded from Hold to Buy on, Wednesday, October 25th, 2017
  • Adnan Butt of "Guggenheim" Initiated at Strong Buy and Held Target at $402 on, Tuesday, October 24th, 2017
  • Christopher Raymond of "Piper Sandler" Initiated at Buy and Held Target at $390 on, Monday, October 23rd, 2017
  • Ying Huang of "B of A Securities" Maintained at Strong Buy with Increased Target to $365 on, Wednesday, October 18th, 2017
  • Salim Syed of "Mizuho" Upgraded from Hold to Strong Buy on, Tuesday, October 17th, 2017
  • Thomas Shrader of "Stifel" Upgraded from Hold to Strong Buy on, Tuesday, October 17th, 2017
  • Matthew Harrison of "Morgan Stanley" Upgraded from Hold to Buy on, Thursday, October 5th, 2017

Contributing Sources